Drug

Mitomycin

Established medicine

ResearchOngoing clinical research

Also known as 7-Amino-9alpha-methoxymitosane, Jelmyto, MMC, MMC-Mitomycin-C+10 more

7-Amino-9alpha-methoxymitosane, Jelmyto, MMC, MMC-Mitomycin-C, Mito-C, MitoMYcin Ophthalmic, Mitosol, Zusduri, Mutamycin, Mitamycin, Mitomycin C, Mitomycin-C, Mitomycin-X, Mitomycine C.

RxNorm632 ChEMBLCHEMBL105 ATCL01DC03UNII50SG953SK6

Research papers

Active clinical trials

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations

Clinical trial2026-08-28Results expected Q2 2028 · ClinicalTrials.gov

A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)

Clinical trial2026-08-28Results expected Q2 2028 · ClinicalTrials.gov

Safety and Efficacy of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Ovarian, Uterine, Appendiceal, Colorectal, and Gastric Cancer Patients With Peritoneal Carcinomatosis (PC)

Clinical trial2026-08-20Results expected Q1 2028 · ClinicalTrials.gov

The Phase III Adaptive Radiation and Chemotherapy for Muscle Invasive Bladder Cancer Trial (ARCHER)

Clinical trial2026-08-18Results expected Q2 2030 · ClinicalTrials.gov

REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation

Clinical trial2026-08-14Primary completion · ClinicalTrials.gov

Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer

Clinical trial2026-08-04Results expected Q2 2027 · ClinicalTrials.gov

Randomized Phase II Trial of Pembrolizumab and Radiation vs. Radiation and Concurrent Chemotherapy for High-Grade T1 Bladder Cancer (PARRC Trial)

Clinical trial2026-07-31Results expected Q1 2032 · ClinicalTrials.gov

Guidance of Adjuvant Instillation in Intermediate Risk Non-muscle Invasive Bladder Cancer by Drug Screens in Patient Derived Organoids. A Single Center, Open-label, Phase II Trial With a Feasibility Endpoint. (GAIN-INST-TRIAL)

Clinical trial2026-07-13Status changed to Active, not recruiting · ClinicalTrials.gov

A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)

Clinical trial2026-07-10Results expected Q4 2029 · ClinicalTrials.gov

A Multicenter, Phase III, Randomized Controlled Clinical Trial of Sintilimab Versus Mitomycin in Combination With Capecitabine and Intensity-Modulated Radiotherapy in the Treatment of Limited-stage Anal Squamous Cell Carcinoma

Clinical trial2026-07-09Results expected Q1 2029 · ClinicalTrials.gov

2022 Peritoneal Surface Oncology Group International Consensus on HIPEC Regimens for Peritoneal Malignancies: Colorectal Cancer.

Research2023-11-08Annals of surgical oncology

A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer.

Research2014-02-03International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Mitomycin

Aliases & brands

7-Amino-9alpha-methoxymitosaneJelmytoMMCMMC-Mitomycin-CMito-CMitoMYcin OphthalmicMitosolZusduriMutamycinMitamycinMitomycin CMitomycin-CMitomycin-XMitomycine C

RxNorm CUI

632

ChEMBL ID

CHEMBL105

ATC codes

L01DC03

UNII

50SG953SK6

Clinical trials

158 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

158

registered trials across all phases

LATEST COMPLETION 2025

Active studies

Recruiting

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 158

Early Phase 14Phase 119Phase 1 / 28Phase 257Phase 2 / 37Phase 344Phase 411Phase N / A8

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder Cancer

RecruitingPH IVJakob Kristian Jakobsenn=2722032

Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC

CompletedPH IVJørgen Bjerggaard Jensenn=1202025

A Prospective Randomized Clinical Trial Comparing Three Delivery Methods of Mitomycin-C for Trabeculectomy Surgery: Preoperative Subconjunctival Injection, Intraoperative Subconjunctival Injection, and Topical Application (Conventional Use) During Trabeculectomy Surgery

TerminatedPH IVUniversity of California, Los Angelesn=192022

Primary Tube Versus Trabeculectomy Study

CompletedPH IVUniversity of Miamin=2422021

The Effects of Sequential Mitomycin and Bacillus Calmette-Guérin Treatment Versus Bacillus Calmette-Guérin Monotherapy in Patients With High Risk Non-Muscle Invasive Bladder Cancer

Unknown statusPH IVAzienda Ospedaliera "Sant'Andrea"n=1402021

Recent completions

Trials that read out recently, adding to the completed evidence base.

Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC

CompletedPH IVJørgen Bjerggaard Jensenn=1202025

A Phase II Trial of Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN BLADDER)

CompletedPH IIFox Chase Cancer Centern=782025

Phase II Trial of Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies

CompletedPH IIWashington University School of Medicinen=482024

Phase II Trial of Cytoreduction + Hyperthermic Intraperitoneal Mitomycin-C+ Standard Systemic Therapy In Patients With Peritoneal Carcinomatosis

CompletedPH IIAlbert Einstein College of Medicinen=512024

Phase II Trial of Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology

CompletedPH IINational Cancer Institute (NCI)n=272024

Intralesional Injection of Mitomycin C Following Visual Internal Urethrotomy for Recurrent Urethral Stricture

CompletedPH II/IIIAin Shams Universityn=502023

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

20142024

Most influential

A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer.

International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2014 · 48 cites

2022 Peritoneal Surface Oncology Group International Consensus on HIPEC Regimens for Peritoneal Malignancies: Colorectal Cancer.

Annals of surgical oncology · 2024 · 27 cites